Advertisement
UK markets closed
  • FTSE 100

    8,275.38
    +44.33 (+0.54%)
     
  • FTSE 250

    20,730.12
    +59.25 (+0.29%)
     
  • AIM

    805.79
    +3.10 (+0.39%)
     
  • GBP/EUR

    1.1742
    -0.0007 (-0.06%)
     
  • GBP/USD

    1.2738
    +0.0006 (+0.05%)
     
  • Bitcoin GBP

    53,193.93
    +159.22 (+0.30%)
     
  • CMC Crypto 200

    1,427.53
    -1.04 (-0.07%)
     
  • S&P 500

    5,277.51
    +42.03 (+0.80%)
     
  • DOW

    38,686.32
    +574.84 (+1.51%)
     
  • CRUDE OIL

    77.18
    -0.73 (-0.94%)
     
  • GOLD FUTURES

    2,347.70
    -18.80 (-0.79%)
     
  • NIKKEI 225

    38,487.90
    +433.77 (+1.14%)
     
  • HANG SENG

    18,079.61
    -150.58 (-0.83%)
     
  • DAX

    18,497.94
    +1.15 (+0.01%)
     
  • CAC 40

    7,992.87
    +14.36 (+0.18%)
     

Iridex to Report First Quarter 2024 Financial Results on May 14, 2024

IRIDEX Corporation
IRIDEX Corporation

MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter 2024 after the close of trading on Tuesday, May 14, 2024.

The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at: www.iridex.com.

About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.

ADVERTISEMENT

MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions.  © 2024 Iridex Corporation.  All rights reserved.

Investor Relations Contact:
Philip Taylor
Gilmartin Group
investors@iridex.com